These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35277655)

  • 21. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
    Wang C; McGraw KL; McLemore AF; Komrokji R; Basiorka AA; Al Ali N; Lancet JE; Padron E; Kosmider O; Fontenay M; Fenaux P; List AF; Sallman DA
    Haematologica; 2022 Mar; 107(3):737-739. PubMed ID: 34320786
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
    Adès L; Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Eclache V; Delaunay J; Bouscary D; Visanica S; Turlure P; Bresler AG; Cabrol MP; Banos A; Blanc M; Vey N; Delmer A; Wattel E; Chevret S; Fenaux P
    Haematologica; 2012 Feb; 97(2):213-8. PubMed ID: 21993675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
    Almeida A; Fenaux P; Garcia-Manero G; Goldberg SL; Gröpper S; Jonasova A; Vey N; Castaneda C; Zhong J; Beach CL; Santini V
    Leuk Lymphoma; 2018 Sep; 59(9):2135-2143. PubMed ID: 29322849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
    Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
    Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
    [No Abstract]   [Full Text] [Related]  

  • 25. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
    Heise C; Carter T; Schafer P; Chopra R
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-emergent mutations in myelodysplastic syndrome with del(5q) - lenalidomide related or disease-intrinsic clonal evolution?
    Abdallah M; Reichard K; Gangat N; Tefferi A
    Blood Cancer J; 2024 Mar; 14(1):49. PubMed ID: 38499527
    [No Abstract]   [Full Text] [Related]  

  • 27. Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial.
    Sockel K; Bornhaeuser M; Mischak-Weissinger E; Trenschel R; Wermke M; Unzicker C; Kobbe G; Finke J; Germing U; Mohr B; Greiner J; Beelen D; Thiede C; Ehninger G; Platzbecker U;
    Haematologica; 2012 Sep; 97(9):e34-5. PubMed ID: 22952334
    [No Abstract]   [Full Text] [Related]  

  • 28. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
    List A
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
    Wei S; Chen X; Rocha K; Epling-Burnette PK; Djeu JY; Liu Q; Byrd J; Sokol L; Lawrence N; Pireddu R; Dewald G; Williams A; Maciejewski J; List A
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12974-9. PubMed ID: 19470455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
    Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
    Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of
    Gangat N; Bellam N; Reichard K; Tefferi A
    Haematologica; 2024 Apr; 109(4):1306-1309. PubMed ID: 38031760
    [No Abstract]   [Full Text] [Related]  

  • 32. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare tetraploidy with large 5q deletion in acute myeloid leukemia with myelodysplasia-related changes (AML-MRC).
    Jarosova M; Nedomova R; Hubacek J; Holzerova M; Mickova P; Katrincsakova B; Pikalova Z; Papajik T; Indrak K
    Leuk Res; 2012 Apr; 36(4):e68-70. PubMed ID: 22284693
    [No Abstract]   [Full Text] [Related]  

  • 34. Role of lenalidomide in the treatment of myelodysplastic syndromes.
    Komrokji RS; List AF
    Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.
    Pellagatti A; Fernandez-Mercado M; Di Genua C; Larrayoz MJ; Killick S; Dolatshad H; Burns A; Calasanz MJ; Schuh A; Boultwood J
    Leukemia; 2014 May; 28(5):1148-51. PubMed ID: 24365791
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
    Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
    Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
    Palacios-Campos A; Gutierrez O; Fabian-Morales E; Avilés A; Candelaria M
    Rev Med Chil; 2020 Sep; 148(9):1357-1361. PubMed ID: 33399713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
    List A; Ebert BL; Fenaux P
    Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients.
    Douet-Guilbert N; De Braekeleer E; Basinko A; Herry A; Gueganic N; Bovo C; Trillet K; Dos Santos A; Le Bris MJ; Morel F; Eveillard JR; Berthou C; De Braekeleer M
    Leukemia; 2012 Jul; 26(7):1695-7. PubMed ID: 22290067
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.